For A2AR, the agonist HENECA (125, 126) influences the immune response within the tumor microenvironment by increasing AC level and intracellular cAMP and suppressing p38 MAPK and activating transcription factor-2 (ATF-2) phosphorylation. The gene discussed is ATF2; the disease is neoplasm.